Table 3.
Univariate and multivariate analysis of baseline variables affecting OS in patients receiving TACE
| Factors | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| HR | 95% CI | P Value | HR | 95% CI | P Value | |
| Gender: M/F | 1.098 | 0.395-3.053 | 0.858 | |||
| Age: ≥ 40 | 0.557 | 0.258-1.201 | 0.135 | |||
| Baseline HBsAg (IU/mL) | 1 | 1-1 | 0.977 | |||
| Baseline HBeAg (PEIU/ml) | 1.003 | 0.991-1.014 | 0.665 | |||
| Baseline Anti-HBe (PEIU/ml) | 1.032 | 0.927-1.147 | 0.567 | |||
| Baseline HBV DNA level, lg copies/mL | 1.053 | 0.904-1.226 | 0.506 | |||
| Anti-HBc: > 11.88 (S/CO) | 0.183 | 0.074-0.484 | 0.001 | 0.066 | 0.013-0.340 | 0.010 |
| AFP (ng/mL): > 200 | 16.674 | 5.021-55.38 | 0.000 | 7.763 | 1.367-43.797 | 0.020 |
| ALT (U/L): > 40 | 1.408 | 0.817-2.428 | 0.218 | |||
| AST (U/L): > 40 | 1.519 | 0.780-2.960 | 0.218 | |||
| PLT (109/L): < 125 | 0.788 | 0.452-1.374 | 0.401 | |||
| ALB (g/L): < 40 | 1.250 | 0.654-2.388 | 0.499 | |||
| TBIL (µmol/L): > 20.5 | 1.053 | 0.603-1.837 | 0.856 | |||
| PT (S): > 13 | 0.809 | 0.429-1.525 | 0.512 | |||
| Blood type: A/B/AB/O | - | - | 0.863 | - | - | |
| BCLC stage: B/C | - | - | 0.009 | - | - | 0.706 |
| Child-Pugh: B | 2.217 | 1.181-4.164 | 0.013 | 0.648 | 0.317-1.325 | 0.234 |
| Diabetes | 2.023 | 1.159-3.530 | 0.013 | 0.669 | 0.357-1.257 | 0.212 |
| Tumor Size (cm): 3-5/> 5 | - | - | 0.000 | - | - | 0.055 |
| Vascular invasion | 11.787 | 3.627-38.302 | 0.000 | 7.022 | 1.589-31.032 | 0.010 |
TACE transarterial chemoembolization, HR hazard ratio, CI confidence Interval, HBsAg hepatitis B surface antigen, HBeAg hepatitis B e antigen, Anti-HBe hepatitis B e antibody, Anti-HBc hepatitis B core antibody, AFPα-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, PLT platelet count, ALB albumin, TBIL total bilirubin, PT prothrombin time, BCLC stage Barcelona Clinic Liver Cancer stage.